Abstract-Recently, ␣ 2 -adrenoceptor activation was shown to play an important role in the vasoconstriction of normal coronary arteries, whereas in the presence of atherosclerosis, the activation of both ␣ 1 -and ␣ 2 -adrenoceptors reduces coronary blood flow in humans. ␣ 2 -Adrenoceptors activate pertussis toxin (PTX)-sensitive G proteins, whereas ␣ 1 -adrenoceptors couple to PTX-insensitive G proteins. Thus, the 825T allele of the ␤3 subunit of heterotrimeric G proteins, associated with enhanced PTX-sensitive G protein signaling, was expected to determine the ␣ 2 -adrenoceptor-, but not the ␣ 1 -adrenoceptor-, mediated reduction in coronary blood flow (CBF). Genotyping was performed on 48 individuals. Twelve of the 48 received the ␣ 1 -adrenoceptor agonist methoxamine (MTX; 5 mg IC), and 12 received the ␣ 2 -adrenoceptor agonist BHT 933 (BHT; 5 mg IC). Twenty-four additional individuals received both MTX and BHT during the same investigational procedure. CBF was calculated on the basis of coronary angiography and intracoronary Doppler flow velocity measurement. Drug-related ischemia was assessed on the basis of ST-segment changes and angina pectoris. In response to BHT, but not to MTX, CBF was reduced to a significantly greater extent in 825T allele carriers (58Ϯ4%, nϭ16) than in individuals homozygous for the C825 allele (28Ϯ4%, nϭ19, Pϭ0.001). This finding was independent of cholesterol levels, mean arterial blood pressure, and the presence or absence of coronary artery disease. Ischemic events in response to BHT occurred more frequently in 825T allele carriers than in homozygous 825C allele carriers (Pϭ0.01). With the use of immortalized lymphoblasts and skin fibroblasts from patients with essential hypertension who display enhanced activation of pertussis toxin (PTX)-sensitive G proteins, we recently described a polymorphism (C825T) in the human gene GNB3 encoding for the ␤3 subunit of heterotrimeric G proteins (G␤3). 1 The 825T allele appears to cause alternative splicing of the gene encoding for G␤3, thereby contributing to the generation of a functionally active splice variant, referred to as G␤3s. Because enhanced PTX-sensitive G protein activation seemed to be the common phenotype in 825T allele carriers, 1 we hypothesized that genotyping at the GNB3 825 locus allows, for the first time, the prediction of the efficacy by which hormones activate PTX-sensitive G proteins and the strength of subsequent cellular responses in humans. After this hypothesis, we recently reported that chemotaxis of neutrophils, which is mediated via ␤␥ subunits released from PTX-sensitive G protein ␣ subunits, is significantly enhanced in 825T allele carriers expressing G␤3s. 2 Stimulated by these findings, we became interested in whether these in vitro observations can be generalized and extended to more complex physiological in vivo responses. In this context, ␣-adrenergic coronary vasoconstriction is an interesting candidate, because the involved ␣-adrenoceptors represent typical heptahelical G protein-coupled receptors. 3 Because the 825T allele seems to exclusively enhance PTX-sensitive G protein signaling, we hypothesized that ␣ 2 -adrenergic activation, which was recently shown to occur via PTX-sensitive G proteins containing the G␤3 subunit, 4 but not ␣ 1 -adrenergic activation, which occurs via PTX-insensitive G proteins, causes enhanced coronary constriction in 825T allele carriers.
H eterotrimeric G proteins composed of ␣, ␤, and ␥ subunits are important components of intracellular signal transduction and ultimately responsible for the transduction of hormonal activation of heptahelical receptors into complex physiological responses, including cell proliferation, chemotaxis, and vasoconstriction.
With the use of immortalized lymphoblasts and skin fibroblasts from patients with essential hypertension who display enhanced activation of pertussis toxin (PTX)-sensitive G proteins, we recently described a polymorphism (C825T) in the human gene GNB3 encoding for the ␤3 subunit of heterotrimeric G proteins (G␤3). 1 The 825T allele appears to cause alternative splicing of the gene encoding for G␤3, thereby contributing to the generation of a functionally active splice variant, referred to as G␤3s. Because enhanced PTX-sensitive G protein activation seemed to be the common phenotype in 825T allele carriers, 1 we hypothesized that genotyping at the GNB3 825 locus allows, for the first time, the prediction of the efficacy by which hormones activate PTX-sensitive G proteins and the strength of subsequent cellular responses in humans. After this hypothesis, we recently reported that chemotaxis of neutrophils, which is mediated via ␤␥ subunits released from PTX-sensitive G protein ␣ subunits, is significantly enhanced in 825T allele carriers expressing G␤3s. 2 Stimulated by these findings, we became interested in whether these in vitro observations can be generalized and extended to more complex physiological in vivo responses. In this context, ␣-adrenergic coronary vasoconstriction is an interesting candidate, because the involved ␣-adrenoceptors represent typical heptahelical G protein-coupled receptors. 3 Because the 825T allele seems to exclusively enhance PTX-sensitive G protein signaling, we hypothesized that ␣ 2 -adrenergic activation, which was recently shown to occur via PTX-sensitive G proteins containing the G␤3 subunit, 4 but not ␣ 1 -adrenergic activation, which occurs via PTX-insensitive G proteins, causes enhanced coronary constriction in 825T allele carriers.
We recently demonstrated in humans that in normal coronary vessels, predominantly ␣ 2 -adrenoceptor activation reduces coronary blood flow (CBF), mainly through microvascular constriction. 5 In the presence of atherosclerosis, both ␣ 1 -and ␣ 2 -adrenergic epicardial and microvascular constric-tions of human coronary vessels are augmented and can then induce myocardial ischemia. 5 Although these findings account for part of the pathophysiological role of ␣-adrenergic coronary vasoconstriction, a common gene variation, such as the C825T polymorphism at GNB3, which determines G protein signaling, might account for the wide range of interindividual variability of ␣-adrenoceptor-mediated coronary constrictor responses.
Materials and Methods

Patients
Forty-eight white individuals undergoing coronary angiography due to chest pain of unknown cause were enrolled consecutively in this study after providing written informed consent. Enrollment was completed when the diagnostic coronary angiography and intravascular ultrasound examination yielded either a normal left coronary artery or single-vessel disease that was suitable for quantitative evaluation. Normal coronary arteries were defined when patients had no plaques or had plaques with Ͻ10% area stenosis in the major left coronary arteries on intravascular ultrasound examination. Demographic data are given in Table 1 .
Twelve individuals received the selective ␣ 1 -adrenoceptor agonist methoxamine (MTX) and 12 individuals received the selective ␣ 2 -adrenoceptor agonist BHT-933 (BHT), both intracoronarily (IC) and in random order. Twenty-four additional individuals received both MTX and BHT in random order during the same investigational procedure. Individuals were divided into 4 groups depending on the ␣-agonist they received and on the presence or absence of coronary artery disease (CAD).
Study Protocol
The study protocol was approved by the local ethics committee of the University of Essen Medical School. With the exception of 100 mg/d aspirin, all medication was stopped 24 hours before cardiac catheterization. Aortic pressure measurement, biplane left ventricular angiography, intravascular ultrasound examination, and coronary catheterization were performed and intracoronary Doppler flow velocity measurements were made as previously described. 5 One individual of the BHT group had to be excluded from further analysis because the quality of the Doppler signal was not satisfactory.
After the intravenous injection of 1 mg atropine to prevent reflex bradycardia, the respective ␣-adrenoceptor agonists were administered in a dose of 5 mg IC each as a bolus via the guiding catheter. Based on our previous study, a dose of 5 mg of each agonist was expected to result in clear coronary vasomotor effects. 5 Doppler flow velocity, arterial blood pressure, and ECG were recorded continuously.
Occurrence of Myocardial Ischemia
Drug-related ischemia was assumed if chest pain was reported or if ST-segment depression of Ն0.2 mV occurred on the ECG within 10 minutes after the injection of the respective drug.
Genotyping
DNA extraction and genotyping were performed in a blinded fashion as previously described. 1
Statistical Analysis
The results are expressed as meanϮSEM. Data were analyzed with the use of the SPSS software package 8.0.0G (SPSS Inc). Categorical data were compared with the use of the 2 test or the Fisher exact test, where appropriate. An exact test was used to determine whether the null hypothesis of an odds ratio of 1 for the occurrence of ischemic events could be rejected. Intragroup variations, as well as comparisons between groups with regard to mean aortic blood pressure (MAP), heart rate (HR), and cholesterol levels, were performed with the use of the Student t test. 6 Because several factors were reported to influence coronary vasomotion, a general linear model was used that included cholesterol levels, 7 
Results
Demographic and clinical data for individuals with different genotypes at GNB3 in each drug group were comparable (Table 1) . Genotyping yielded 2 individuals who were ho- 
␣ 2 -Adrenoceptor Activation
The CBF reduction induced by BHT was significantly larger in 825T allele carriers than in homozygous C825 allele carriers (58Ϯ4% versus 28Ϯ4%, Pϭ0.001; Figure 1 ) and significantly enhanced in patients with CAD compared with patients without CAD (53Ϯ5 versus 30Ϯ5%, Pϭ0.04; Figure 2 ). In individuals with the homozygous CC genotype, CBF was markedly reduced in response to ␣ 2 -adrenoceptor activation and further reduced in the presence of CAD (39Ϯ8% versus 20Ϯ3%, Pϭ0.02. Although CBF reduction was even greater in 825T allele carriers, the additional effect of CAD was rather moderate (64Ϯ5% versus 48Ϯ7%, Pϭ0.07).
In 8 patients with an average CBF reduction of 55Ϯ10%, clinical signs of acute ischemia, as represented by STsegment depression or symptoms of angina pectoris, were observed in response to BHT (Table 2 ). This effect was almost exclusively observed in heterozygous 825T allele carriers with (3 TC and 1 CC) and without (4 TC) CAD. The resulting odds ratio for ischemia in response to BHT was significantly increased in 825T allele carriers (odds ratio, 14.0; 95% confidence interval, 1.5 to 132; Pϭ0.01; Table 3 ).
␣ 1 -Adrenoceptor Activation
The MTX-induced CBF reduction was not significantly different between genotypes at the GNB3 locus (CC, 46Ϯ5%; TC, 31Ϯ6%; Pϭ0.2; Figure 1 ) but strongly enhanced in patients with CAD (53Ϯ4 versus 19Ϯ5%; Pϭ0.003; Figure 2) . Three patients (2 TC, 1 CC) displayed clinical signs of ischemia (mean CBF reduction, 36Ϯ27%; Table 3 ).
Discussion
In the experimental setting, ␣-adrenergic coronary constriction is overcome by metabolic dilation under physiological circumstances 11 but is sufficiently powerful to reduce CBF when local regulatory mechanisms are impaired by endothelial dysfunction, 12 atherosclerosis, 13 autoregulatory escape, 14 or distal to severe stenoses. 15, 16 In patients with CAD, isometric exercise and reflex sympathetic activation can induce ischemic myocardial dysfunction and angina pectoris, which are in part caused by ␣-adrenergic coronary vasoconstriction. [17] [18] [19] Both ␣ 1 -and ␣ 2 -adrenoceptor activation play an important role in coronary vasoconstriction. In our previous study, in normal coronary arteries, CBF was mainly reduced through the activation of ␣ 2 -adrenoceptors, whereas in atherosclerotic coronary arteries, both ␣ 1 -and ␣ 2 -adrenoceptor activation contributed equally to the reduction in blood flow. 5 Somewhat different from our previous investigation but consistent with the study of Lorenzoni et al, 20 in the present study, we found a small but significant decrease in blood flow in normal human coronary vessels on ␣ 1 -adrenoceptor activation. This difference can most likely be explained from a statistical point of view, because the number of patients in the previous study was probably not sufficient to achieve significance in differentiation between several doses of the ␣ 1 -agonist. We observed a large interindividual variability in CC/TC/TT indicates homozygosity and heterozygosity for C825 or 825T alleles at GNB3; OR, odds ratio for the occurrence of ischemic events; and CI, confidence interval.
Ischemia is defined as chest pain or ST-segment depression of Ն0.2 mV on the ECG within 10 minutes after the injection of study drug.
vasoconstrictor responses to ␣-adrenoceptor activation. Given the enhanced responsiveness of PTX-sensitive G proteins in individuals carrying the GNB3 825T allele, we hypothesized that a large fraction of the variability seen on ␣ 2 -adrenoceptor, but not ␣ 1 -adrenoceptor, activation is determined by genotype. In fact, we could now demonstrate that the presence of an 825T allele was a strong predictor of selective ␣ 2 -adrenergic coronary vasoconstriction, independent of MAP, HR, and cholesterol levels. Even more remarkable was that this effect was independent of coronary artery status, which also contributed to CBF reduction in response to BHT, potentially through impaired coronary vasodilator capacity in the presence of endothelial damage. However, with the use of a descriptive analysis, the impact of CAD was markedly lower in 825T allele carriers.
As expected, no differences occurred with respect to genotype at GNB3 on selective ␣ 1 -adrenoceptor activation, whereas the CBF reduction was significantly enhanced in patients with CAD, in line with our previous observations. 5 In response to BHT, the 825T allele carriers also significantly more often displayed clinical signs of ischemia, which was most likely due to the greater CBF reduction, because further analysis of data from our previous study 5 indicated that the decrease in myocardial lactate extraction, as an indicator of myocardial ischemia, is significantly correlated to the reduction of CBF in response to 5 mg IC of the respective study drug (Spearman's Rϭ0.725, Pϭ0.008). Interestingly, we recently reported that the presence of an 825T allele also increases the likelihood for myocardial infarction in individuals with CAD. 21 Although these findings improve our pathophysiological understanding, especially of patients with abnormal vascular reactions and angina pectoris symptoms in the absence of any flow-limiting epicardial coronary stenosis, the physiological importance of this observation remains to be defined. No investigation has been performed in vivo, with the use of norepinephrine as the endogenous adrenoceptor activator or physical activity, to evaluate the distinct impact of ␣ 1 -and ␣ 2 -adrenoceptors on CBF under physiological circumstances in humans.
The molecular basis of the observed association between ␣ 2 -adrenergic activation and genotype at GNB3 has yet to be determined. ␣ 2 -Adrenoceptors regulate vascular tone via 2 distinct mechanisms. First, they may mediate vasoconstriction through the inhibition of adenylyl cyclases and activation of phospholipase C, with the latter process involving G protein ␤␥ subunits. 22, 23 Second, ␣ 2 -adrenoceptor activation mediates vasodilation, which is assumed to be secondary to the release of nitric oxide from the endothelium. 24 Thus, one could speculate that the enhanced blood flow reduction in 825T allele carriers may be counteracted by a concomitantly increased vasodilation. However, ␣ 2 -adrenoceptor activation in vivo usually causes vasoconstriction that is not overcome by vasodilation, with the latter mainly observed under in vitro conditions (eg, in preconstricted, isolated arteries). Furthermore, although ␣ 2 -adrenoceptor-mediated vasodilation seems to involve nitric oxide formation via PTX-sensitive G proteins in large conductance arteries, 24 in other vascular beds, such as in coronary arteries, 25 cerebral arteries, 26 or mesenterial resistance arteries, 27 nitric oxide either seems to have no effect or inhibits ␣ 2 -adrenoceptor-mediated vasodilation. Not much is known about the mechanisms of the nitric oxide-independent, ␣ 2 -adrenoceptor-mediated vasodilation, although a very recent report suggests the involvement of smooth muscle Ca 2ϩ -operated K ϩ channels. 27 
Conclusions
Beyond the augmentation of ␣ 1 -and ␣ 2 -adrenergic coronary vasoconstriction in the presence of coronary atherosclerosis, the response to ␣ 2 -adrenoceptor activation is likely genetically determined and is strongly associated with the 825T allele at GNB3. The enhanced coronary vasoconstrictor response in 825T allele carriers with and without CAD was accompanied by a higher rate of signs and symptoms of myocardial ischemia.
